NXTSTIM has announced 18-month data from a real-world study showing that its wearable transcutaneous electrical nerve and electromyographic stimulation device, EcoAI, can help relieve pain.
The real-world study enrolled 550 adult patients with different pain sites, such as back pain, neck pain, shoulder pain, and knee pain. After 18 months of using EcoAI, 92% of patients reported pain improvement compared to baseline scores. About 66% of the patients showed at least a 40% improvement in visual analogue pain scale scores compared to baseline.
“This is the first large real-world demonstration of using the EcoAI AIML technology combined with remote patient monitoring to show durable outcomes,鈥� said Prachi Patel MD on behalf of study investigators.
鈥淲ith no adverse events reported and significant pain relief in over 66% of patients out to 18 months, this is a landmark approach to pain care using a front-end electroceutical solution.”
The wearable technologies have seen high growth in recent years. As per a , the market size of wearable technology in the medical sector in 2023 is projected to exceed $100bn and is expected to grow at a compound annual growth rate of 15% up to 2030. The neuromodulation market is also projected to grow from being worth approximately $7bn in 2023 to $10.7bn in 2030, as per GlobalData market analysis.
The EcoAI device works by blocking pain signal transmission from the peripheral nervous system to the central nervous system. It has a pre-set choice of programmes based on historical clinical data and evidence. It also uses AI to record patient data and provide individualised patient neurostimulation programmes.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe patient places a gel pad on the body part where they feel pain. Then the patient can control the device via phone using Bluetooth.
The NXSTIM electroceutical device can also serve as a remote patient monitoring tool. It has been cleared for use by the US Food and Drug Administration as a remote monitoring device that delivers transcutaneous electrical nerve stimulation and electrical muscle stimulation.
